Filing Details

Accession Number:
0000899243-20-032667
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-03 16:05:08
Reporting Period:
2020-12-01
Accepted Time:
2020-12-03 16:05:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1767321 R. Matthew Henn C/O Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-01 26,000 $0.71 38,000 No 4 M Direct
Common Stock Acquisiton 2020-12-01 26,250 $9.89 64,250 No 4 M Direct
Common Stock Acquisiton 2020-12-01 27,562 $6.01 91,812 No 4 M Direct
Common Stock Disposition 2020-12-01 55,706 $26.56 36,106 No 4 S Direct
Common Stock Disposition 2020-12-01 26,265 $27.56 9,841 No 4 S Direct
Common Stock Disposition 2020-12-01 9,841 $28.34 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-12-01 26,000 $0.00 26,000 $0.71
Common Stock Stock Option (Right to Buy) Disposition 2020-12-01 26,250 $0.00 26,250 $9.89
Common Stock Stock Option (Right to Buy) Disposition 2020-12-01 27,562 $0.00 27,562 $6.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-09-19 2024-08-06 No 4 M Direct
3,750 2024-08-06 No 4 M Direct
45,938 2029-01-24 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.07 to $27.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.10 to $28.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.145 to $28.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The option has vested as to 25% of the shares on January 26, 2018. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.
  6. The option has vested as to 25% of the shares on January 25, 2020. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.